A NEW EFFECTIVE TREATMENT FOR INDOLENT LYMPHOMA - A PILOT-STUDY WITH FLUDARABINE, IDARUBICIN AND PREDNISONE COMBINATION (FLIDA)

The management of indolent lymphomas is still controversial. Intensive therapies may improve remission rate but in association with toxicity . Fludarabine and idarubicin are very active drugs in indolent lymphom as. This pilot trial was designed to evaluate the efficacy of a regime n comprising fludarabine, idarubicin and prednisone (FLIDA) in the tre atment of low-grade non-Hodgkin's lymphoma at diagnosis. We have asses sed the response of 16 adult patients (median age 57 years, range 45-7 1 years) treated on an outpatient basis: the overall response rate was 93.8 per cent (CR 43.8 per cent, PR greater than or equal to 50 per c ent). The toxicity of this regimen was very low, with no relevant hema tological and infectious complications. (C) 1997 John Wiley & Sons, Lt d.